DK1745295T3 - Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein - Google Patents

Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein

Info

Publication number
DK1745295T3
DK1745295T3 DK05744241.0T DK05744241T DK1745295T3 DK 1745295 T3 DK1745295 T3 DK 1745295T3 DK 05744241 T DK05744241 T DK 05744241T DK 1745295 T3 DK1745295 T3 DK 1745295T3
Authority
DK
Denmark
Prior art keywords
amyloid
production
inhibit
gpcr
beta
Prior art date
Application number
DK05744241.0T
Other languages
English (en)
Inventor
Pascal Gerard Merchiers
Koenraad Frederik Florentina Spittaels
Marcel Hoffmann
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of DK1745295T3 publication Critical patent/DK1745295T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05744241.0T 2004-04-20 2005-04-20 Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein DK1745295T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56366104P 2004-04-20 2004-04-20
PCT/EP2005/004325 WO2005103713A2 (en) 2004-04-20 2005-04-20 Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Publications (1)

Publication Number Publication Date
DK1745295T3 true DK1745295T3 (da) 2011-01-31

Family

ID=35197590

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05744241.0T DK1745295T3 (da) 2004-04-20 2005-04-20 Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein

Country Status (10)

Country Link
US (3) US7429459B2 (da)
EP (3) EP2270513A3 (da)
JP (1) JP4890442B2 (da)
AT (1) ATE483981T1 (da)
CA (1) CA2605574A1 (da)
DE (1) DE602005023976D1 (da)
DK (1) DK1745295T3 (da)
ES (1) ES2353604T3 (da)
SI (1) SI1745295T1 (da)
WO (1) WO2005103713A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1745295T3 (da) * 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
WO2008033518A2 (en) * 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
GB0700645D0 (en) * 2007-01-12 2007-02-21 Eisai London Res Lab Ltd Targets for disease therapy
US20090053140A1 (en) * 2007-05-15 2009-02-26 Roderick Euan Milne Scott METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
CN101808647A (zh) * 2007-05-15 2010-08-18 海利空医疗公司 通过抑制Gpr12治疗认知障碍的方法
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
EP2440934B1 (en) * 2009-06-08 2014-07-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US9757398B2 (en) 2010-02-20 2017-09-12 Euroespes Biotecnnologia, S.L. Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate
US20130331330A1 (en) * 2012-06-08 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase
US20150065376A1 (en) * 2013-08-12 2015-03-05 Holger Knaut Expression constructs encoding g protein coupled receptors and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6090575A (en) * 1995-03-30 2000-07-18 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPR1
US5998164A (en) * 1995-03-30 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPRZ
WO1996030406A1 (en) * 1995-03-30 1996-10-03 Human Genome Sciences, Inc. Human g-protein coupled receptors
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6420563B1 (en) 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
KR20020015307A (ko) 1999-02-26 2002-02-27 리처드 피. 버군 쥬니어 Ｇ 단백질 결합 수용체 ６의 소형 분자 조절제
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
JP2003531638A (ja) * 2000-05-03 2003-10-28 アストラゼネカ アクチボラグ 食欲制御物質の同定のためのｇタンパク質共役型受容体ｇｐｒ３の使用
WO2001090128A2 (en) * 2000-05-24 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the gpr3 gene
US7163800B2 (en) * 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
WO2003071272A1 (en) * 2002-02-22 2003-08-28 Takeda Chemical Industries, Ltd. Method of determining ligand
WO2003097795A2 (en) * 2002-05-13 2003-11-27 Norak Biosciences, Inc. Constitutively translocating cell line
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20040023380A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 6 expression
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
AU2003301892A1 (en) * 2002-11-04 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1662862A1 (en) * 2003-09-19 2006-06-07 Paradigm Therapeutics Limited Receptor
DK1745295T3 (da) * 2004-04-20 2011-01-31 Galapagos Nv Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein

Also Published As

Publication number Publication date
DE602005023976D1 (de) 2010-11-18
ES2353604T3 (es) 2011-03-03
EP2267458A3 (en) 2011-04-06
WO2005103713A3 (en) 2006-09-08
US20110118338A1 (en) 2011-05-19
JP4890442B2 (ja) 2012-03-07
SI1745295T1 (sl) 2011-01-31
EP2270513A2 (en) 2011-01-05
EP1745295B1 (en) 2010-10-06
US7429459B2 (en) 2008-09-30
WO2005103713A2 (en) 2005-11-03
EP2267458A2 (en) 2010-12-29
EP1745295A2 (en) 2007-01-24
US20050266502A1 (en) 2005-12-01
CA2605574A1 (en) 2005-11-03
HK1099810A1 (en) 2007-08-24
US20090005262A1 (en) 2009-01-01
EP2270513A3 (en) 2011-04-06
ATE483981T1 (de) 2010-10-15
US7910320B2 (en) 2011-03-22
JP2007533989A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2005108949A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
Meredith Jr et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer’s disease
Pirttimaki et al. α7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical Alzheimer’s mouse model
DK2046951T3 (da) Proteasesreeningsmetoder og proteaser identificeret dermed
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
DK2126586T3 (da) Direkte bestemmelse af vitamin D i serum eller plasma
DK1745295T3 (da) Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein
Huesgen et al. Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease
DK2185937T3 (da) Fremgangsmåde til at bestemme sepsis hos mennesker
US20170037472A1 (en) Methods for the treatment of kidney fibrosis
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
DK2005190T4 (da) Inhibering af GASC1
EA201491411A1 (ru) Растворимый manf при поражениях бета-клеток поджелудочной железы
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
UA107789C2 (en) Method based on biomarkers designed to monitor treatment
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
WO2005119262A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103693A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2005103715A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
NO20053990L (no) Assay for proteinisoformer
DK1929015T3 (da) Dobbelt fluorescerende reporterkonstrukt og test til måling af translationel genkodning
ATE455305T1 (de) Verfahren zur bestimmung des verhältnisses von zwei verschiedenen peptiden oder polynukleinsäuren
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer
DE602005015108D1 (de) Methode für die Analyse von Substanzen gegen Flaviviren unter Verwendung eines persistent Virus-infizierten Zellsystems
Chew et al. Fluorescent quantitation method for differentiating the nativity of green fluorescent protein